" class="no-js "lang="en-US"> Vertex & CRISPR Therapeutics Submit License Applications
Thursday, June 08, 2023

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the FDA

Vertex Pharmaceuticals and CRISPR Therapeutics today announced the completion of the rolling Biologics License Applications (BLAs) to the United States Food and Drug Administration (FDA) for the investigational treatment exagamglogene autotemcel (exa-cel) for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The BLAs include requests for Priority Review, which if granted, would shorten the FDA’s review of the application to eight months from the time of submission versus a standard review timeline of 12 months.

These submissions are supported by results from the ongoing Phase 3 studies, CLIMB-111 and CLIMB-121, as well as an ongoing long-term follow-up study, CLIMB-131. Data from the Phase 3 studies were most recently presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in December of 2022.

“The completion of our exa-cel global regulatory filings is a historic milestone,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex Pharmaceuticals. “We want to thank the clinical trial participants and the sickle cell and beta thalassemia communities, as well as the physicians, nurses, coordinators, caregivers and friends who support them.”

“Within a decade, we have progressed from the discovery of the CRISPR platform to the first regulatory filings for a CRISPR-based therapy, which speaks to the transformative nature of CRISPR technology,” said Phuong Khanh (P.K.) Morrow, M.D., FACP, Chief Medical Officer at CRISPR Therapeutics.

In the U.S., exa-cel has been granted Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA for both SCD and TDT.

In Europe, the Marketing Authorization Applications (MAAs) for exa-cel were submitted in December 2022 and validated by the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in January 2023. In the EU, exa-cel has been granted Orphan Drug Designation from the European Commission, as well as Priority Medicines (PRIME) designation from the EMA, for both SCD and TDT. In the U.K., exa-cel has also been granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the MHRA.

Companies In This Post

  1. EpimAb Biotherapeutics Appoints Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer Read more
  2. Mendus and NorthX Biologics to Enter into Strategic Cell Therapy Manufacturing Alliance Supported by New Investor Flerie Read more
  3. SciTech Development Raises $2.73 Million in Oversubscribed Funding Round to Advance Clinical Trials for Cancer Treatment Read more
  4. Amarna Therapeutics Announces Appointment of Dr. Henk Streefkerk as New CEO Read more
  5. Aegis Life Awarded Grant to Develop DNA-encoded Antibodies Against Infectious Diseases Read more